ANTI-ACE2-CYTOPLASMIC CLONE 1C17 ZOOMAB RABBIT MONOCLONAL (C005B-261525)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1C17 is a Rabbit recombinant monoclonal antibody that specifically detects Angiotensin-converting enzyme 2 (ACE2). It targets an epitope within 21 amino acids from the C-terminal region.

Immunogen

KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal, cytoplasmic domain of human Angiotensin-converting enzyme 2 (ACE2).

Application

Quality Control Testing

Evaluated by Western Blotting in HepG2 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected ACE2-cytoplasmic in HepG2 cell lysate.

Tested applications

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 and 1:100 dilution of this antibody detected ACE2-cytoplasmic in human kidney and human lung tissue sections, respectively.

.

Affinity Binding Assay: A representative lot of this antibody bound ACE2-cytoplasmic domain with a KD of 10.0 x 10-9 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected ACE2-cytoplasmic in HepG2 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Angiotensin-converting enzyme 2 (UniProt: Q9BYF1; also known as EC:3.4.17.23, Angiotensin-converting enzyme homolog, ACEH, Angiotensin-converting enzyme-related carboxypeptidase, ACE-related carboxypeptidase, Metalloprotease MPROT15) is encoded by the ACE2 (also known as UNQ868/PRO1885) gene (Gene ID: 59272) in human. Angiotensin-converting enzyme (ACE) and its homolog ACE2 belong to the ACE family of dipeptidyl carboxydipeptidases and are known to serve two opposing functions. ACE cleaves angiotensin I to generate angiotensin II that binds to angiotensin receptor leading to constriction of blood vessels and hypertension. ACE2 is a single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-17), which is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 18-740), a transmembrane domain (aa 741-761), and a cytoplasmic domain (aa 762-805). By contract, ACE2 is reported to inactivate angiotensin II while generating angiotensin 1 7, a heptapeptide with vasodilator function via activation of its Mas receptor. ACE2 expression in airway epithelial cells is induced by viruses such rhinoviruses, influenza virus, and SARS-CoV-2. SARS-CoV and SARS-CoV-2 utilize ACE2 as receptor for entry into cells and the receptor binding domain of SARS-Cov-2 displays strong interaction with human ACE2 molecules. The receptor binding domain (RBD) of spike protein serves as the binding interface with the ACE2 receptor. High ACE2 expression is reported in type II alveolar cells of lung, esophagus, absorptive enterocytes of ileum and colon, and kidney proximal tubule cells. These organs are considered as higher potential risk for SARS-CoV-2 infection. In animal models it is shown that treatment with Angiotensin converting enzyme inhibitors (ACEI) and Angiotensin receptor blockers (ARBs) can increase the expression of ACE2 in various organs and may increase their risk and severity of SARS-CoV-2 infection. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Yang, J., et al. (2020). Nat. Commun. 11(1); Article 4541; Hoffmann, M., et al. (2020). Cell 181(2); 271-280).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.